Discontinued — last reported Q4 '17
Non-Current Assets
Intangibles (Net)
Eli Lilly Intangibles (Net) increased by 1.2% to $6.52B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $6.17B to $6.52B. Over 5 years (FY 2020 to FY 2025), Intangibles (Net) shows a downward trend with a -2.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryMarket Position
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2017
How to read this metric
High levels reflect significant investment in growth through acquisitions; changes indicate the impact of amortization or impairment charges.
Detailed definition
This includes the value of acquired intellectual property, such as patents, trademarks, and drug licenses, net of accumu...
Peer comparison
Very high in the pharmaceutical industry due to the reliance on patent-protected drug portfolios.
Metric ID:
intangible_assets_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.99B | $7.89B | $7.69B | $7.48B | $7.50B | $7.12B | $7.21B | $7.09B | $6.90B | $6.78B | $6.91B | $6.76B | $6.64B | $6.54B | $6.17B | $6.01B | $5.91B | $6.45B | $6.52B |
| QoQ Change | — | -1.2% | -2.5% | -2.7% | +0.2% | -5.0% | +1.2% | -1.7% | -2.6% | -1.8% | +1.8% | -2.1% | -1.9% | -1.5% | -5.7% | -2.5% | -1.7% | +9.1% | +1.2% |
| YoY Change | — | — | — | — | -6.1% | -9.7% | -6.3% | -5.3% | -7.9% | -4.8% | -4.2% | -4.6% | -3.9% | -3.6% | -10.7% | -11.1% | -11.0% | -1.4% | +5.8% |
Range$5.91B – $7.99B
CAGR-4.4%
Avg YoY Growth-5.6%
Median YoY Growth-5.3%
Current Streak2 quarters growth
Intangibles (Net) at Other Companies
Frequently Asked Questions
- What is Eli Lilly's intangibles (net)?
- Eli Lilly (LLY) reported intangibles (net) of $6.52B in Q4 2025.
- How has Eli Lilly's intangibles (net) changed year-over-year?
- Eli Lilly's intangibles (net) increased by 5.8% year-over-year, from $6.17B to $6.52B.
- What is the long-term trend for Eli Lilly's intangibles (net)?
- Over 5 years (2020 to 2025), Eli Lilly's intangibles (net) has grown at a -2.6% compound annual growth rate (CAGR), from $7.45B to $6.52B.
- What does intangibles (net) mean?
- The value of non-physical assets like patents and brand names, minus their amortized cost.